NCT02039947 2019-05-21Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the BrainNovartisPhase 2 Completed127 enrolled 17 charts
NCT01978236 2018-08-17Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and MetabolitesGlaxoSmithKlinePhase 2 Terminated6 enrolled 9 charts